Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Accelerated Phase 2Down Syndrome 2Blast Crisis 2Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Rituximab 5Lenalidomide 5Cytarabine 5Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 1 year × Clear all
NCT02458014 2025-09-23

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡